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Abstract
Background: This study was undertaken to compare the accuracy of chronic kidney disease-epidemiology
collaboration (eGFRCKD-EPI) to modification of diet in renal disease (eGFRMDRD) and the Cockcroft-Gault formulas of
Creatinine clearance (CCG) equations in predicting post coronary artery bypass grafting (CABG) mortality.
Methods: Data from 4408 patients who underwent isolated CABG over a 11-year period were retrieved from one
institutional database. Discriminatory power was assessed using the c-index and comparison between the scores’
performance was performed with DeLong, bootstrap, and Venkatraman methods. Calibration was evaluated with
calibration curves and associated statistics.
Results: The discriminatory power was higher in eGFRCKD-EPI than eGFRMDRD and CCG (Area under Curve [AUC]:0.77,
0.55 and 0.52, respectively). Furthermore, eGFRCKD-EPI performed worse in patients with an eGFR ≤29 ml/min/1.73m
2
(AUC: 0.53) while it was not influenced by higher eGFRs, age, and body size. In contrast, the MDRD equation was
accurate only in women (calibration statistics p = 0.72), elderly patients (p = 0.53) and subjects with severe
impairment of renal function (p = 0.06) whereas CCG was not significantly biased only in patients between 40 and
59 years (p = 0.6) and with eGFR 45–59 ml/min/1.73m2 (p = 0.32) or ≥ 60 ml/min/1.73m2 (p = 0.48).
Conclusions: In general, CKD-EPI gives the best prediction of death after CABG with unsatisfactory accuracy and
calibration only in patients with severe kidney disease. In contrast, the CG and MDRD equations were inaccurate in
a clinically significant proportion of patients.
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Background
Preoperative renal impairment is a well-established pre-
dictor of adverse outcomes in patients undergoing cor-
onary artery bypass grafting (CABG) [1–3]. In addition,
with advances in the fields of nephrology, cardiology,
and cardiac surgery, an increasing number of patients
with renal dysfunction are being offered coronary
revascularization [4].Therefore, accurate preoperative
evaluation of renal function is recommended before
CABG [5].
Estimated glomerular filtration rate (eGFR) is now
considered a more sensitive marker of renal function
than serum creatinine alone identifying patients with
even mild renal impairment despite normal or nearly
normal creatinine levels [6–8].
Different formulas to estimate eGFR have been
implemented [1, 2, 9] and, amongst these, the Modifi-
cation of Diet in Renal Disease (MDRD) equation
(eGFRMDRD) [1, 2, 9], the more recently defined
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(CKDEPI) equation (eGFRCKD-EPI) [10, 11]along with
the Cockcroft-Gault equation formula of Creatinine
Clearance (CCG)[7, 8, 12]are the most widely
employed.
The predictive value of eGFR on mortality and mor-
bidity following CABG has been widely demonstrated [9,
10, 11, 12]. Nonetheless, papers have concentrated on
patients with serum creatinine or eGFR calculated by
the CCG equation or MDRD [2, 13, 14] and, at the best
of our knowledge, no study exists comparing eGFRMDRD
and CCG. eGFRCKD-EPI in their predictive value of post-
CABG mortality.
Therefore, in this study we test the reliability of these
three formulae in predicting mortality after CABG and
compare their discrimination and calibration power. In
addition, discrimination and calibration of the three
models were also evaluated in relation to factors that
may influence the absolute bias of the equations [15].
Methods
This study was performed in accordance with the Dec-
laration of Helsinki and following STROBE guidelines
[16]. Consecutive patients undergoing isolated CABG at
Careggi Hospital (Florence, Italy) between 2006 and
2017 were retrospectively enrolled in the study.
Definitions
Definitions and calculations were as in our previous
research [17]. Kidney dysfunction was defined following
the recently updated Kidney Disease Outcomes Quality
Initiative (KDOQI) [18] and Kidney Disease Improving
Global Outcomes (KDIGO) Guidelines [7].
The CCG [19], MDRD [20] and Chronic Kidney
Disease (CKD)-EPI estimate of renal function were cal-
culated as recommended [15, 21] and normalized to
1.73 m2 of the body surface area (BSA) [22] and
expressed in ml/min/1.73m2. The body mass index
(BMI) was calculated as body weight divided by the
square of height, with body weight expressed in kg and
height in meters.
Endpoint
The single endpoint was all-cause mortality within 30
days after CABG (n = 3880 cases, 79 deaths) or during
index procedure hospitalization- in case of postoperative
length of stay > 30 days (n = 528 cases, 36 deaths) which
was reported via hospital records or registry
information.
Statistical analysis
Continuous data were summarized as mean and standard
deviation or median and twenty-fifth to seventy-fifth per-
centiles in case of skewed distributions. Frequencies were
reported for categorical variables. The performances of CCG
vs. eGFRCKD-EPI vs. eGFRMDRD were analyzed to determine
their discrimination power and calibration [23, 24]. The dis-
crimination performance was assessed by receiver operating
characteristic (ROC) and the area under the curve (AUC)
with 95% confidence intervals [25–27]. Curves were ana-
lyzed with De Long, bootstrap, and Venkatraman methods
[27]. Furthermore, the model was tested by Somers’ test as-
suming predictions as perfectly discriminating when
Dxy = 1 [28]. Moreover, we employed the Brier score
and when it was equal to 0 the prediction could be
considered perfect [29].
The calibration performance can be evaluated by gen-
erating calibration plots: the perfect calibrated predic-
tions stay on the diagonal, whilst a curve below or above
it, respectively, reflects overestimation and underestima-
tion [23, 27, 30].
Agreement between observed frequency and predicted
probabilities were tested with the Hosmer-Lemeshow
(H-L) goodness-of-fit test, whereas the comparison of
actual slope and intercept with the ideal value of 1 and 0
was performed with the U statistic and tested against a
χ2 distribution with 2 degrees of freedom.
Discrimination and calibration performances were
stratified by renal function, gender, age, body weight,
and BMI due to the fact that these variables might influ-
ence the performance of the equations. Stratification of
calculated eGFR (≥ 60 ml/min/1.73m2;45–59ml/min/
1.73m2, 30–44 ml/min/1.73m2 and ≤ 29ml/min/1.73m2)
was based on updated KDOQI and KDIGO [7, 19] and
according to level of calculated EGFR, as well as on the
basis of the estimates of the Cockcroft- Gault, MDRD,
and CKD-EPI formulas. Using Cohen’s k we tested the
agreement between calculated and estimated EGFR .
Clinical cutoffs were used for age (18 to 39, 40 to 59,
and ≥ 60 years) [31] and body weight (≤59, 60 to 79, 80
to 99, and ≥ 100 kg) [12]. Stratification for BMI followed
the World Health Organization guidelines [32]. To
address missing values (Additional file 1), we used fully
conditional specification [33] (FCS) multiple imputation
(MI) method (1000 replications).
R, version 3.3.1 (R Foundation for Statistical Comput-
ing, Wien, Austria) with pROC, rms and Resource Selec-
tion packages was employed to carry out statistical
analysis.
Significance for hypothesis testing was set at the 0.05
two-tailed level.
Results
Study population
After exclusion of subjects without an available plasma
creatinine level (n = 86), body weight (n = 73) or height
(n = 37) measurements, those undergoing preoperative
dialysis (n = 18), who had undergone previous cardiac
surgery (n = 108), who experienced significant (life-
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threatening) post-operative complications (n = 396) or
with mitral insufficiency ≥ moderate (n = 174) the final
population consisted of 4408 subjects who remained eli-
gible for inclusion. Patient characteristics are presented
in Table 1.
Mortality
Overall early mortality was 2.6% (n = 115): it was 24/
2440 (1%) in patients with EGFR ≥60ml/min/1.73m2,
20/1170 (1.7%) in those with EGFR between 45 and 59
ml/min/1.73m2, 39/703 (5.5%) in subjects with EGFR
ranging from 30 to 44 ml/min/1.73m2 and 32/95 (33.6%)
in those with EGFR ≤29ml/min/1.73m2.
Overall performance
Results of Predictive Performance, Discrimination Power
and Calibration are shown in Tables 2 and 3. The c Stat-
istic and the other measures of performance showed that
only the CKD-EPI formula had any notable discrimin-
atory power. The MDRD formula shows borderline sig-
nificant discrimination, given the lower confidence limit
for the C statistic is 0.50 The CG formula shows no evi-
dence of being able to discriminate between those who
died and those who did not. The ROC curves are plotted
in Fig. 1 a-c: The AUC was higher in eGFRCKD-EPI than
in the other two and all the comparisons amongst them
showed significant differences between the three formu-
las with best performance by eGFRCKD-EPI.
The pattern of calibration (Fig. 1 d-f) was different be-
tween the three indices. Indeed, eGFRCKD-EPI was closer
to the ideal line with a slight under-prediction when risk
was higher but with non-significant p values for the cali-
bration statistics (both, p = 0.40). In contrast, eGFRMDRD
and CCG diverged significantly from the ideal diagonal
with significant p values for the related summary statis-
tics (both, p = 0.02).
Performance by kidney function
Patients with a higher eGFR were younger (− 0.13 years
[95%CI 0.11–1.1] per ml/min/1.73m2 increment in
eGFR) with a higher body weight (1.64 kg [95%CI 1.41–
2.89]) and a higher BMI (0.62 kg/m2 [95%CI 0.48–0.96]).
The analysis of discrimination in the subgroups demon-
strated an overall worse performance of eGFRMDRD,
(Fig. 2a-c) with significant differences when eGFR was >
29ml/min/1.73m2. In contrast, when the eGFR was ≤29
ml/min/1.73m2 the performance of MDRD was superior
(p = 0.14). CCG showed comparable performance of
eGFRCKD-EPI when eGFR was > 44 ml/min/1.73m
2.
The pattern of calibration was different in the different
subgroups of patients (Fig. 2 e-f: eGFRCKD-EPI demon-
strated a satisfactory calibration with eGFR > 29ml/min/
1.73m2 but with non-significant p values for the calibra-
tion statistics (p = 0.58, p = 0.78, p = 0.39, in the three
Table 1 Patient characteristics (n = 4408)
Baseline Characteristics
Age 70.7 [64.5–76.2]
Female sex 902 (20.5)
BSA 1.85 ± 0.17
BMI 26.2 ± 3.8
Diabetes 793 (17.9)
COPD 154 (3.5)
PVD 525 (11.9)
CVD 26 (0.6)
MI < 30 days 873 (19.8)
Unstable Angina 1494 (33.9)
≥ 3 vessels disease 2579 (58.5)
LVEF 48.5 [42.1–57.6]
Creatinine (mg/dL) 1.09 [0.91–1.31]
EuroScore 8.9 [4.5–12.2]
STS Score 9.9 [4.8–13.1]
STS PROM 9.2 [4.2–12.8]
eGFRMDRD
≥ 60 2494 (56.6)
45–59 1200 (27.2)
30–44 638 (14.5)
≤ 29 76 (1.7)
eGFRCKD-EPI
≥ 60 2597 (58.9)
45–59 1097 (24.9)
30–44 633 (14.4)
≤ 29 81 (1.8)
CCG
≥ 60 2440 (55.4)
45–59 1170 (26.5)
30–44 703 (15.9)
≤ 29 95 (2.2)
Operative Characteristics
1 graft 264 (6.0)
2 grafts 1943 (44.1)
≥ 3 grafts 2201 (49.9)
OPCAB 1983 (44.9)
Data are shown as mean ± SD or numbers (percentage) or median
[Interquartile range]. Abbreviations. BSA: Body Surface Area; BMI: Body Mass
Index; COPD: Chronic Obstructive Pulmonary Disease; PVD: Peripheral Vascular
Disease; CVD: Cerebrovascular Disease; MI: Myocardial Infarction; LVEF: Left
Ventricular Ejection Fraction; STS: Society of Thoracic Surgeons; PROM:
Predicted risk of mortality; eGFRMDRD: Glomerular Filtration Rate estimated by
the Modification in Diet in Renal Disease; eGFRCKD-EPI: (ml/min/1.73 m2)
Glomerular Filtration Rate estimated by Chronic Kidney Disease-Epidemiology
Collaboration equation (ml/min/1.73 m2); CCG: Creatinine Clearance estimated
by Cockroft-Gault formula (ml/min/1.73 m2); OPCAB: Off-Pump Coronary
Artery Bypass
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Table 2 Predictive performance and discrimination power
eGFR AUC 95% CI De Long Bootstrap Venkatraman Somers Brier
All CKD-EPI 0.77 0.73–0.81 < 0.01* < 0.01* < 0.01* 0.54 0.01
MDRD 0.55 0.50–0.61 0.65† 0.61† 0.76† 0.11 0.02
CG 0.52 0.47–0.57 < 0.01‡ < 0.01‡ < 0.01‡ 0.04 0.02
eGFR > = 60ml/min./1.73m2 CKD-EPI 0.78 0.73–0.82 < 0.01* < 0.01* < 0.01* 0.55 0.01
MDRD 0.57 0.50–0.63 < 0.01† < 0.01† < 0.01† 0.13 0.02
CG 0.73 0.69–0.75 0.57‡ 0.54‡ 0.60‡ 0.44 0.01
45–59 ml/min./1.73m2 CKD-EPI 0.67 0.57–0.77 < 0.01* < 0.01* < 0.01* 0.34 0.01
MDRD 0.59 0.49–0.69 < 0.01† < 0.01† < 0.01† 0.18 0.02
CG 0.65 0.60–0.69 0.67‡ 0.66‡ 0.69‡ 0.30 0.01
30–44 ml/min./1.73m2 CKD-EPI 0.63 0.55–0.71 0.04* 0.04* 0.04* 0.25 0.03
MDRD 0.53 0.40–0.67 0.45† 0.43† 0.55† 0.07 0.05
CG 0.57 0.43–0.71 0.04‡ 0.04‡ 0.04‡ 0.15 0.04
<=29ml/min./1.73m2 CKD-EPI 0.53 0.35–0.71 0.35* 0.32* 0.54* 0.06 0.13
MDRD 0.65 0.48–0.82 0.10† 0.09† 0.16† 0.30 0.14
CG 0.49 0.27–0.71 0.23‡ 0.20‡ 0.28‡ 0.02 0.13
Age AGE > =60 y CKD-EPI 0.68 0.63–0.74 < 0.01* < 0.01* < 0.01* 0.37 0.02
MDRD 0.57 0.51–0.63 0.58† 0.52† 0.63† 0.14 0.03
CG 0.54 0.48–0.60 < 0.01‡ < 0.01‡ < 0.01‡ 0.09 0.03
AGE 40–59 y CKD-EPI 0.81 0.70–0.92 < 0.01* < 0.01* < 0.01* 0.62 0.02
MDRD 0.59 0.48–0.70 < 0.01† < 0.01† < 0.01† 0.17 0.03
CG 0.86 0.80–0.91 0.45‡ 0.41‡ 0.52‡ 0.72 0.01
AGE 18–39 y CKD-EPI 0.82 0.72–0.96 < 0.01* < 0.01* < 0.01* 0.64 0.06
MDRD 0.57 0.46–0.72 0.03† 0.02† 0.04† 0.14 0.09
CG 0.47 0.08–0.85 < 0.01‡ < 0.01‡ < 0.01‡ 0.06 0.12
Gender Male CKD-EPI 0.76 0.71–0.82 < 0.01* < 0.01* < 0.01* 0.53 0.01
MDRD 0.55 0.49–0.61 0.04† 0.04† 0.04† 0.10 0.02
CG 0.51 0.45–0.57 < 0.01‡ < 0.01‡ < 0.01‡ 0.03 0.02
Female CKD-EPI 0.72 0.66–0.78 < 0.01* < 0.01* < 0.01* 0.44 0.02
MDRD 0.55 0.43–0.66 0.03† 0.03† 0.04† 0.09 0.04
CG 0.50 0.43–0.57 < 0.01‡ < 0.01‡ < 0.01‡ 0.01 0.06
Weight > = 100 Kg CKD-EPI 0.81 0.66–0.97 0.01* 0.01* 0.02* 0.63 0.05
MDRD 0.50 0.31–0.70 0.04† 0.04† 0.04† 0.01 0.07
CG 0.48 0.26–0.69 < 0.01‡ < 0.01‡ < 0.01‡ 0.04 0.08
80–99 Kg CKD-EPI 0.77 0.69–0.84 < 0.01* < 0.01* < 0.01* 0.53 0.01
MDRD 0.52 0.41–0.62 0.04† 0.04† 0.04† 0.04 0.02
CG 0.50 0.40–0.62 < 0.01‡ < 0.01‡ < 0.01‡ 0.03 0.03
60–79 Kg CKD-EPI 0.79 0.74–0.84 < 0.01* < 0.01* < 0.01* 0.59 0.01
MDRD 0.56 0.49–0.63 0.02† 0.02† 0.03† 0.12 0.02
CG 0.50 0.43–0.57 < 0.01‡ < 0.01‡ < 0.01‡ 0.01 0.03
<=59 Kg CKD-EPI 0.69 0.56–0.83 0.01* 0.03* 0.02* 0.39 0.03
MDRD 0.55 0.41–0.69 0.48† 0.45† 0.56† 0.11 0.03
CG 0.53 0.38–0.68 < 0.01‡ < 0.01‡ < 0.01‡ 0.07 0.04
BMI > = 30 Kg/m2 CKD-EPI 0.81 0.71–0.92 < 0.01* < 0.01* < 0.01* 0.63 0.01
MDRD 0.53 0.37–0.69 0.03† 0.03† 0.04† 0.06 0.02
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groups with eGFR > 29 ml/min/1.73m2, respectively).
However, it tended to under- influence of predict mor-
tality when eGFR was ≤29 ml/min/1.73m2 (p = 0.04).
In contrast, eGFRMDRD was well calibrated at values of
eGFR ≤29 ml/min/1.73m2 (p = 0.06) whereas it diverged
significantly from perfect calibration when eGFR was
higher than 29 ml/min/1.73m2 (p = 0.02, p = 0.03, p =
0.04, in the three groups with eGFR > 29 ml/min/1.73m2,
respectively). Finally, CCG tended to over-prediction
when eGFR was < 44ml/min/1.73m2 (p = 0.03).
Performance by age
Older patients had lower eGFR (− 0.93 ml/min/1.73m2
[95%CI 0.71–1.13] per yearly increment in age), had a
lower body weight (− 1.73 kg [95%CI 1.51–2.29]) and a
lower BMI (− 0.56 kg/m2 [95%CI 0.48–0.75]). The AUC
of the ROC curves (Fig. 3 a-c) was significantly higher
for eGFRCKD-EPI in all subgroups. CCG performed better
the MDRD equation in the range of 40–59 years whereas
it showed the worst performance of the three groups
< 40 years.
The pattern of calibration was different amongst age
subgroups (Fig. 3 d-f): eGFRCKD-EPI was close to the
ideal diagonal in the oldest patients whereas it tended to
slightly overestimate in the other age groups with non-
significant p values for the calibration statistics (p =
0.69). The eGFRMDRD resulted to be well calibrated in
the ≥60 year- subgroup (p = 0.53) whereas it demon-
strated a significant tendency to over-estimation in the
other age subgroups (all, p < 0.05). Finally, CCG tended
to over-prediction in the ≥60 year- and 18–39 year-sub-
groups (both, p = 0.03).
Performance by gender
Compared with men, woman had a lower body weight
(− 11.4 kg [95%CI 4.4–12.4]) and a lower BMI (− 1.65 kg/m2
[95%CI 1.14–6.65]).
The eGFRCKD-EPI equation showed a higher AUC in
both genders (Fig. 4 a-c) with significant differences
compared to the CCG and MDRD equations (p < 0.05 for
all comparisons). CCG showed a worse performance
compared to eGFRMDRD in both genders.
In men (Fig. 4 d-f) eGFRCKD-EPI reached maximum
accuracy whereas it showed a tendency to overesti-
mation in women although calibration statistics were
not significant in (both,p = 0.1). In contrast, eGFRMDRD was
accurate in women (p = 0.72) and tended to overesti-
mation in men (p = 0.03) whereas CCG significantly over-
estimated in both sexes (both, p = 0.03).
Performance by BMI
Subjects with a higher BMI were younger (− 0.22 years
[95%CI 0.09–0.44] each kg/m2), had a higher body
weight (2.89 kg [95%CI 2.73–3.21] each kg/m2) and a
higher eGFR (0.78 ml/min/1.73m2 [95%CI 0.56–0.91]
each kg/m2).
The AUC of ROC curves (Fig. 5 a-c) were higher
with eGFRCKD-EPI no matter what the BMI subgroup
was (p < 0.05 for all comparisons). The calibration
curves are shown in Fig. 5 D-F: the eGFRCKD-EPI
equation was close to the ideal diagonal at any value
of BMI with a slight lower accuracy in patients with
BMI < 25.0 kg/m2 (p = 0.03). In contrast, the MDRD
was more accurate in patients with BMI < 25.0 kg/m2
(p = 0.7) whereas it showed a trend to over-
prediction in subjects with BMI ≥25.0 kg/m2 (p =
0.03 and p = 0.04 in patients with BMI 25–29 Kg/m2
and ≥ 30 Kg/m2, respectively). Finally, the CCG for-
mula was the less accurate up to 18.5 kg/m2 (p =
0.03, p = 0.02 and p = 0.02 in patients with BMI > 30
Kg/m2, 25–29 Kg/m2 and ≥ 30 Kg/m2, respectively)
with a tendency to over-prediction, while it was
comparable to the MDRD formula when in patients
with BMI < 25.0 kg/m2 (p = 0.5).
Table 2 Predictive performance and discrimination power (Continued)
eGFR AUC 95% CI De Long Bootstrap Venkatraman Somers Brier
CG 0.46 0.28–0.64 < 0.01‡ < 0.01‡ < 0.01‡ 0.06 0.03
25–29 Kg/m2 CKD-EPI 0.76 0.70–0.82 < 0.01* < 0.01* < 0.01* 0.52 0.01
MDRD 0.55 0.47–0.63 0.01† < 0.01† 0.02† 0.10 0.02
CG 0.45 0.37–0.53 < 0.01‡ < 0.01‡ < 0.01‡ 0.01 0.04
18.5–24 Kg/m2 CKD-EPI 0.77 0.70–0.83 < 0.01* < 0.01* < 0.01* 0.53 0.01
MDRD 0.57 0.49–0.66 0.00† < 0.01† 0.01† 0.15 0.02
CG 0.47 0.39–0.56 < 0.01‡ < 0.01‡ < 0.01‡ 0.04 0.04
<=18.5 Kg/m2 CKD-EPI 0.77 0.62–0.92 0.04* 0.04* 0.04* 0.54 0.14
MDRD 0.52 0.27–0.66 0.65† 0.62† 0.70† 0.03 0.13
CG 0.53 0.13–0.94 < 0.01‡ < 0.01‡ < 0.01‡ 0.07 0.12
Best performance for: Brier score = 0, AUC = 1, Somers’ Dxy = 1. Abbreviations: eGFR: estimated Glomerular Filtration Rate; CI: Confidence Interval; CKD-EPI: Chronic
Kidney Disease-Epidemiology Collaboration Formula; MDRD: Modification of Diet in Renal Disease Formula; CG: Cockroft-Gault Formula; BMI: Body Mass Index.*
CKD-EPI vs MDRD; † MDRD vs CG; ‡ CG vs CKD-EPI
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Table 3 Calibration
eGFR Slope Intercept U statistic Hosmer-Lemeshow
All CKD-EPI 0.69 0.12 0.38 0.40
MDRD 1.34 −1.06 0.03 0.04
CG 1.29 −1.00 0.02 0.02
eGFR > = 60ml/min/1.73m2 CKD-EPI 0.60 0.15 0.21 0.58
MDRD 1.20 −1.16 0.03 0.02
CG 0.57 0.18 0.39 0.48
45–59 ml/min/1.73m2 CKD-EPI 0.54 −0.14 0.15 0.78
MDRD 1.17 1.56 0.02 0.03
CG 0.59 0.20 0.28 0.32
30–44 ml/min/1.73m2 CKD-EPI 0.49 0.18 0.09 0.39
MDRD 0.22 −0.16 0.02 0.04
CG 0.28 −0.17 0.03 0.03
<=29ml/min/1.73m2 CKD-EPI 1.13 0.58 0.04 0.04
MDRD 1.07 −0.36 0.07 0.06
CG 1.23 −0.28 0.04 0.03
Age AGE > =60 y CKD-EPI 1.03 0.30 0.10 0.69
MDRD 0.91 −0.04 0.43 0.53
CG 0.63 −1.35 0.02 0.03
AGE 40–59 y CKD-EPI 0.66 −0.24 0.25 0.41
MDRD 0.60 −1.77 0.02 0.03
CG 0.92 −0.03 0.56 0.60
AGE 18–39 y CKD-EPI 0.75 −0.88 0.32 0.37
MDRD 0.71 −1.75 0.02 0.03
CG 0.59 −1.65 0.01 0.02
Gender Male CKD-EPI 0.85 0.36 0.20 0.10
MDRD 0.70 −1.67 0.03 0.03
CG 0.84 −1.43 0.02 0.03
Female CKD-EPI 0.65 −0.30 0.30 0.19
MDRD 0.81 0.89 0.44 0.72
CG 0.79 −1.33 0.03 0.03
Weight > = 100 Kg CKD-EPI 0.77 −0.28 0.39 0.49
MDRD 0.30 −1.43 0.01 0.02
CG 0.50 −1.30 0.02 0.02
80–99 Kg CKD-EPI 0.65 −0.16 0.40 0.64
MDRD 0.20 −1.72 0.02 0.04
CG 0.46 −1.65 0.01 0.02
60–79 Kg CKD-EPI 0.56 0.13 0.19 0.43
MDRD 0.70 0.11 0.31 0.59
CG 0.72 −1.47 0.02 0.02
<=59 Kg CKD-EPI 0.63 0.18 0.10 0.32
MDRD 0.70 0.12 0.39 0.80
CG 0.88 0.20 0.40 0.47
BMI > = 30 Kg/m2 CKD-EPI 0.87 0.13 0.58 0.67
MDRD 0.50 −2.07 0.01 0.04
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Table 3 Calibration (Continued)
eGFR Slope Intercept U statistic Hosmer-Lemeshow
CG 0.47 −1.68 0.01 0.03
25–29 Kg/m2 CKD-EPI 0.75 −0.39 0.50 0.57
MDRD 0.40 −2.05 0.01 0.03
CG 0.40 −1.75 0.02 0.02
18.5–24 Kg/m2 CKD-EPI 0.65 −0.26 0.42 0.86
MDRD 0.70 0.23 0.50 0.70
CG 0.46 −1.42 0.01 0.02
<=18.5 Kg/m2 CKD-EPI 0.85 0.71 0.16 0.36
MDRD 0.80 −0.44 0.48 0.73
CG 0.79 −0.37 0.37 0.50
Best performance for: Slope = 1, Intercept = 0, non-significant P-values of the U statistic, and Hosmer–Lemeshow test. Abbreviations: eGFR: estimated Glomerular
Filtration Rate; CI: Confidence Interval; CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration Formula; MDRD: Modification of Diet in Renal Disease Formula;
BMI: Body Mass Index; CG: Cockroft-Gault Formula
Fig. 1 Receiver operating characteristic curves with 95% confidence intervals for eGFRCKD-EPI (a) eGFRMDRD (b) and CCG (c). A curve lying on the
diagonal line reflects the performance of a diagnostic test that is no better than chance level. The closer is the curve to the upper left-hand
corner the greater is the discriminant testing capacity. Calibration plots of eGFRCKD-EPI (d) and eGFRMDRD (e) and CCG (f). The diagonal line
represents the perfect calibration. If the line lies below the ideal curve, the EGFR formula overestimates the outcome, if it is above the ideal curve
the formula underestimates the outcome
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Discussion
Patients with CAD and renal disease have a dismal prog-
nosis [34, 35]. In addition, estimated glomerular filtra-
tion rate (eGFR) has a major impact on the outcome of
patients undergoing coronary revascularization, either
percutaneous coronary intervention or coronary artery
bypass grafting (CABG) [10, 36] .
Reduced erythropoietin synthesis and consequent
anemia and reduced 1,25(OH) vitamin D production,
associated with increased parathyroid hormone levels
and higher prevalence of vascular calcification and ar-
teriosclerosis have been reported to explain the asso-
ciation between renal dysfunction and cardiovascular
events [37, 38].
In addition, patients with reduced or impaired renal
function face additional challenges in the setting of
CABG for several reasons: 1) Concomitant factors such
as including advanced age, low ejection fraction, history
myocardial infarction, and stroke which are themselves
determinants of poor outcomes [39]. 2) Detrimental
cardiovascular effects by oxidative stress and high levels
of homocysteine, hyperuricemia, hypercalcemia, and
uremia associated with reduced renal function [40, 41].
3) Higher incidence of multivessel disease and microves-
sel disease in such patients [2, 11].
However, little is known whether eGFRs calculated
with different formulas have comparable predictive value
on post-CABG mortality.
In our recent paper [42] we had shown that the
eGFRCKD-EPI equation led to categorization with a sig-
nificantly lower number of patients at risk for post-
CABG complications and with cut-off values of eGFRCK-
D-EPI predicting early and late events significantly lower
than accepted prediction threshold values for post-
CABG unfavorable events [2, 41, 43].
In the present study our study we assessed the per-
formance, in terms of discrimination and calibration, of
the MDRD, CG formulas and CKD-EPI equations in
predicting mortality after CABG in the whole patient
population and across different subgroups of patients
defined by eGFR, age, gender and body size.
The main findings of our study can be summarized as
follows:
1) The overall performance of eGFRCKD-EPI in
prediction of post-CABG death is significantly
Fig. 2 Patients Stratified by Renal Function. Receiver operating characteristic curves with 95% confidence intervals for eGFRCKD-EPI (a) eGFRMDRD
(b). and CCG (c) . Colored curve above the diagonal line perform progressively better the closer they are to the upper left-hand corner. Calibration
plots of eGFRCKD-EPI (d) eGFRMDRD (e) and CCG (f). Lines below the ideal curve (dotted line) overestimate the outcome, if they lie above the ideal
curve the outcome is underestimated
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superior to both eGFRMDRD and CG formulas and
its calibration curve is close to the ideal prediction
over a wide range of thresholds for mortality risk
prediction whereas the MDRD and CG equations,
show a general trend towards over-prediction.
2) The CKD-EPI equation gave the best overall accur-
acy and agreement after classification in subgroups
of GFR. Furthermore, it had a greater accuracy in
patients with an eGFR > 30 ml/min/1.73m2 whereas
it showed a trend towards under-predicting mortal-
ity when the eGFR fell below 30 ml/min/1.73m2. In
contrast, eGFRMDRD confirmed [15] to be the most
reliable in patients with highly compromised renal
function whilst CCG showed comparable perform-
ance of eGFRCKD-EPI when eGFR was > 44 ml/min/
1.73m2.
3) Previous studies have demonstrated that the
performance of eGFR equations depends on the
stage of CKD [44], thus being greatly influenced by
the value of glomerular filtration rate [15]. In
addition, the MDRD equation resulted in imprecise
and underestimates of eGFR at higher renal
function levels [45]. In our experience, the
accurateness of the CKD- EPI formula in predicting
post-CABG mortality was independent of age and
gender whereas eGFRMDRD overestimated the pre-
diction in younger patients and in men while it was
accurate in women and patients ≥60 years and CCG
tended to over-prediction in the ≥60 year- and 18–
39 year-subgroups and in both genders. This might
be related to the uncertain reliability of these for-
mulas in reflecting the true renal function [46, 47]
4) Since all three formulas rely on serum creatinine as
the indicator for the rate of glomerular filtration
and because serum creatinine correlates with
muscle mass and nutritional status, the
performance of the formulas might be influenced by
body composition. This was assessed by studying
the influence of body mass or BMI on eGFR, which,
in our experience, did not affect the CKD-EPI equa-
tion whose calibration curve was close to the ideal
diagonal at any value of BMI. In contrast, the
MDRD was accurate only in overweight patients
and those with body mass ≥ 30.0 kg/m2. These re-
sults are in accordance with Michels et al. [15] who
found that MDRD provided greatest accuracy in
Fig. 3 Patients Stratified by Age. Receiver operating characteristic curves with 95% confidence intervals for eGFRCKD-EPI (a) eGFRMDRD (b) and CCG
(c) stratified by age. Colored curve above the diagonal line perform progressively better the closer they are to the upper left-hand corner.
Calibration plots of eGFRCKD-EPI (d) and eGFRMDRD (e) and CCG (f). Lines below the ideal curve (dotted line) overestimate the outcome, if they lie
above the ideal curve the outcome is underestimated
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defining renal function (97.0%) in subjects with the
highest body weight whereas other studies showed
no relation or positive correlation concluding that
no creatinine-based method is reliable in the obese
[48]. Lastly, the CCG formula was the least accurate
up to 18.5 kg/m2 while it was comparable to the
MDRD formula in smaller patients.
Renal function is regularly included in all risk stratifica-
tion models in cardiac surgical patients. Two well-
recognized risk models assess cardiovascular outcomes of
patients undergoing CABG: the EuroSCORE and the Soci-
ety of Thoracic Surgeons (STS) National Adult Cardiac
Database [49]. The first employs eGFR calculated with CCG
formula and value ranges that are not concordant with Na-
tional Kidney Foundation recommendations [50] whereas
the STS risk score incorporates a continuous parameter for
serum creatinine and a binary variable for hemodialysis
[51]. Based on KDIGO clinical practice Guidelines [8] and
previous evidence [15], it would be of great interest to test,
in a broad patient population, the eGFRCKD-EPI formula in-
corporated into CABG risk prediction algorithm, re-
estimating the weight for all the variables in the predictive
tool, to compare the predictive performance of such a
model to algorithms currently in use. At this point, in the
absence of validation studies, it is impossible to understand
whether the use of eGFRCKD-EPI in stratification models
would make a valuable contribution to improve the predict-
ive value of the algorithm. Further research is warranted.
Study limitations
This study has some limitation that should be
highlighted. Firstly, its retrospective nature makes it
impossible to draw final conclusions. Secondly, the
population is relatively small, and assessment of the
equations was carried out in a restricted study popu-
lation (i.e. post CABG patients), limiting extrapola-
tion of findings to other cohorts such as myocardial
infarction, heart failure etc. Thirdly, the patient
population has several variations from most CABG
profiles: low number of female, low incidence of
adult onset diabetes mellitus, unstable angina and
MI < 30 days and high number of patients receiving
1–2 grafts. Fourthly, patients with associated proce-
dures were excluded and this could introduce an-
other bias. We wanted to test the three indices
Fig. 4 Patients Stratified by Gender. Receiver operating characteristic curves with 95% confidence intervals for eGFRCKD-EPI (a) eGFRMDRD (b) and
CCG (c). . Colored curve above the diagonal line perform progressively better the closer they are to the upper left-hand corner. Calibration plots of
eGFRCKD-EPI (d) eGFRMDRD (e) and CCG (f). Lines below the ideal curve (dotted line) overestimate the outcome, if they lie above the ideal curve the
outcome is underestimated
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excluding as much as possible confounding factors.
Fifthly, preoperative eGFR was calculated on a single
measurement and therefore susceptible of being influ-
enced by cardiac function and therapy. Sixthly, preopera-
tive renal function was unknown which could have post-
CABG survival. Seventhly, eGFRCKD-EPI still has the limi-
tation of being related to muscle mass, thus other filtra-
tion markers such as serum cystatin might have helped us
in overcoming this issue. Eighthly, data presented in this
paper did not say anything about which equation is the
better predictor of true GFR, but it was beyond the aim of
the paper that was explore which eGFR formula is the best
predictor of mortality. The two things may go hand-in-
hand, but this cannot be concluded from the existing data
and it will be object of upcoming research. Finally, neither
we compare the performance of the three formulae within
specific risk scores, nor did not test the performance of
eGFRCKD-EPI on postoperative renal failure but these were
beyond the aim of the present study.
Conclusions
In general, CKD-EPI gives the best prediction of death
after CABG with unsatisfactory accuracy and calibration
only in patients with severe CKD. In contrast, the CG
and MDRD equations were inaccurate in predicting
mortality in a clinically significant proportion of patients.
eGFRCKD-EPI should be incorporated into CABG risk-
assessment algorithms to provide patients and their
family members the most accurate risk prediction.
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